logo

Search

Hyperphosphatemia Drugs Market By Type (Calcium-based Phosphate Binders, Magnesium-based Phosphate Binders, Aluminum-based Phosphate Binders, Iron-based Phosphate Binders, and Other Phosphate Binders), By Dosage Form (Capsules, Tablets, and Syrups), Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2027.

Report ID : 2340 | Publisher ID : Meta | Published : 2023-09-27 | Pages : 255

Licence Type
$ 3550
$ 5350
$ 7100

Market Definition 

Hyperphosphatemia is the high levels of inorganic phosphate in the blood. High phosphate levels in the blood can be reduced by the use of phosphate binders and dietary constraints of phosphates. 

Global hyperphosphatemia drugs market is estimated to reach $XX million by 2027, growing at a CAGR of 16.67% till 2027. 

Market Dynamics 

The rising prevalence and incidence of chronic kidney diseases is a key driving factor of the market. According to the Centers for Disease Control and Prevention, the global prevalence of chronic kidney diseases is 13.4%. According to the Centers for Disease Control and Prevention, around 15% of US adults, which is 37 million people had chronic kidney diseases in 2020. In Canada, around 4 million people have chronic kidney diseases. According to the NHS England, more than 1.8 million people in England were diagnosed with chronic kidney disease (CKD) in 2019. Around 19·5 million have been diagnosed with chronic kidney disease in China. The prevalence of chronic kidney disease was 10.8% in 2019. According to the Australian Institute of Health and Welfare, around 1.7 million (10%) Australian adults with age 18 years and over had biomedical signs of chronic kidney disease (CKD). However, the side effects of hyperphosphatemia drugs might hamper the market growth. Some of the common side effects of hyperphosphatemia drugs include vomiting, nausea, diarrhea, indigestion, abdominal pain, gas, and constipation. Moreover, the high potential of hyperphosphatemia drugs in untapped economies, including India, China, South Africa, and Brazil, would provide lucrative opportunities for the market in coming years. 

Market Segmentation 

The global hyperphosphatemia drugs market is mainly classified based on type and dosage form. Type is further segmented into Calcium-based Phosphate Binders, Magnesium-based Phosphate Binders, Aluminum-based Phosphate Binders, Iron-based Phosphate Binders, and Other Phosphate Binders. By dosage form, the market is divided into Capsules, Tablets, and Syrups.  

Based on dosage form, Tablets has shown significant growth in 2020, owing to the increasing regulatory approval of hyperphosphatemia tablets, the partnership between companies to expand its product portfolio and presence in the global market, and commercialization of new hyperphosphatemia tablets. For instance, Kissei Pharmaceutical Co., Ltd. has introduced P-TOL Granules 250 mg and P-TOL Granules 500 mg in Japan for the treatment of hyperphosphatemia. P-TOL Granules 250 mg and P-TOL Granules 500 mg are new dosage forms of P-TOL Chewable tablets. P-TOL decreases serum phosphate concentration through the binding of oxyhydroxide iron with phosphoric acid in the gastrointestinal tract and reduces in vivo phosphate absorption. 

Regional Analysis 

Based on geography, the global hyperphosphatemia drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided into the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa. 

North America was dominating the global hyperphosphatemia drugs market in 2020 due to the prevalence and incidence of chronic kidney diseases and the increasing prevalence of diabetes & osteoporosis across the region. In North America, the prevalence of chronic kidney diseases is very high in the elderly population, with more than 35% of patients over age 70 years suffering from stage 3 chronic kidney disease. Moreover, increasing regulatory approval for New Drug Application (NDA) for hyperphosphatemia drugs in the United States is boosting the market growth. For instance, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines for the treatment of people with kidney and cardiovascular diseases, has received U.S. Food and Drug Administration (FDA) acceptance for its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. 

Competitive landscape 

Key players operating in the hyperphosphatemia drugs industry include Keryx Biopharmaceuticals, Sun Pharmaceutical, Ultragenyx, Pfizer Inc, Vifor Pharma, Sanofi, Takeda Pharmaceutical, Fresenius Medical Care, Emcure Pharma, and Ardelyx, Inc. 

The collaboration between companies to develop and expand its market presence for hyperphosphatemia drugs, increasing regulatory approval for hyperphosphatemia drugs, strategic acquisition to extend product portfolio and geographic presence and commercialization of new generic version of hyperphosphatemia drugs are some of the strategies adopted by the major companies. For instance, on July 01, 2020, Emcure Pharmaceuticals has introduced a generic version of sucroferric oxyhydroxide tablets, which are indicated for the control of increased serum phosphorus levels in patients with chronic kidney disease on dialysis. The sucroferric oxyhydroxide drug is sold under the brand name 'Dynulta' and is manufactured at the company's facility. 

Hyperphosphatemia Drugs Market Key Segments: 

By Type 

  • Calcium-based Phosphate Binders 
  • Magnesium-based Phosphate Binders 
  • Aluminum-based Phosphate Binders 
  • Iron-based Phosphate Binders 
  • Other Phosphate Binders 

By Dosage Form 

  • Capsules 
  • Tablets 
  • Syrups 

Key Global Hyperphosphatemia Drugs Industry Players 

  • Keryx Biopharmaceuticals 
  • Sun Pharmaceutical 
  • Ultragenyx 
  • Pfizer Inc 
  • Vifor Pharma 
  • Sanofi 
  • Takeda Pharmaceutical 
  • Fresenius Medical Care 
  • Emcure Pharma 
  • Ardelyx, Inc. 

What Report Provides 

  • Full in-depth analysis of the parent Industry 
  • Important changes in market and its dynamics 
  • Segmentation details of the market Former, on-going, and projected market analysis in terms of volume and value 
  • Assessment of niche industry developments 
  • Market share analysis 
  • Key strategies of major players 
  • Emerging segments and regional growth potential 

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope
2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources
3. Hyperphosphatemia Drugs Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Rising Prevalence and Incidence of Chronic Kidney Diseases
3.4. Restraints
3.4.1. Side Effects of Hyperphosphatemia Drugs
3.5. Opportunity
3.5.1. High Potential of Hyperphosphatemia Drugs in Untapped Economy including India, China, South Africa, and Brazil
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis
4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Calcium-based Phosphate Binders
4.2.1. Market Size & Forecast
4.3. Magnesium-based Phosphate Binders
4.3.1. Market Size & Forecast
4.4. Aluminum-based Phosphate Binders
4.4.1. Market Size & Forecast
4.5. Iron-based Phosphate Binders
4.5.1. Market Size & Forecast
4.6. Other Phosphate Binders
4.6.1. Market Size & Forecast
5. Dosage Form Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Capsules
5.2.1. Market Size & Forecast
5.3. Tablets
5.3.1. Market Size & Forecast
5.4. Syrups
5.4.1. Market Size & Forecast
6. Hyperphosphatemia Drugs Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Hyperphosphatemia Drugs Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Dosage Form
6.2.4. U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Hyperphosphatemia Drugs Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Dosage Form
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Hyperphosphatemia Drugs Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Dosage Form
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Hyperphosphatemia Drugs Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Dosage Form
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Hyperphosphatemia Drugs Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Dosage Form
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast
7. Company Profile
7.1. Keryx Biopharmaceuticals
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Keryx Biopharmaceuticals Product Category, Application, and Specification
7.1.3. Keryx Biopharmaceuticals Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Sun Pharmaceutical
7.3. Ultragenyx
7.4. Pfizer Inc
7.5. Vifor Pharma
7.6. Sanofi
7.7. Takeda Pharmaceutical
7.8. Fresenius Medical Care
7.9. Emcure Pharma
7.10. Ardelyx, Inc.

  • Keryx Biopharmaceuticals 
  • Sun Pharmaceutical 
  • Ultragenyx 
  • Pfizer Inc 
  • Vifor Pharma 
  • Sanofi 
  • Takeda Pharmaceutical 
  • Fresenius Medical Care 
  • Emcure Pharma 
  • Ardelyx, Inc. 

n/a

Frequently Asked Questions